Amarin (AMRN)
(Real Time Quote from BATS)
$0.86 USD
-0.01 (-1.35%)
Updated May 23, 2024 12:36 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 181 - 200 ( 359 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Trick or Treat ahead of AHA: Treat With Our Day-by Day Calendar
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
An Ounce of Preparation Is Worth a Pound of Cure
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Management Doesnt Skip a Beat, As Vascepa AdCom Is Announced; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Launch in Infancy, Pivotal Events on Near- Term Horizon, in Our View; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
2Q19 - Ten Reasons Why Vascepa Brings Home the Bacon
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
What Happens If AstraZeneca Launches Epanova? A Look at How Amarins IP May Give It the Upper Hand
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Updated Revenue Guidance Consistent With Proprietary OM-3 Survey; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A